Abstract
Currently, clinicians face a wide gamut of challenges in the treatment of infectious conditions of the skin. Economic factors generated by healthcare management agencies and beyond the control of the clinician may serve to restrict access to specific medications and indirectly restrict patient access to appropriate care. An area of very recent concern is centered on the growing prevalence of methicillin-resistant Staphylococcus aureus. Herpes simplex type 2 prevalence has shown for the first time a surprising downward trend, offsetting the expected continuation in upward escalation observed in previous decades. Newer pharmacological agents have facilitated control of fungal and parasitic infections. More dermatologists are becoming involved in the field of wound care, where appreciation of microbial colonization may play an equally important role to that of frank wound infection. The novel use of biologicals for the treatment of psoriasis heralds the need for constant vigilance for the potential emergence of granulomatous infections, such as TB.
Acknowledgements
We wish to recognize the invaluable assistance we received from Ioanna Agams, Chief Librarian at Hoboken University Medical Center, NJ, USA, for her extraordinary support in the research necessary to compile the material required to write this manuscript.
Financial & competing interests disclosure
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
No writing assistance was utilized in the production of this manuscript.
Notes
US CDC guidelines Citation[304].
Reproduced with permission from Citation[80].
Reproduced with permission from Citation[80].
Data from Citation[215].